Hospital La Paz in Madrid joins RESILIENCE
A new center joins the RESILIENCE project. It is the hospital La Paz in Madrid,…

The RESILIENCE project develop a novel healthcare intervention (Remote Ischemic Conditioning, RIC) aimed at reducing the prevalence of chronic heart failure in cancer survivors.
Remote ischemic conditioning (RIC) is a phenomenon by which brief, reversible episodes of occlusion and re-occlusion in one organ (e.g. an arm) render remote organs resistant to injury.
Cardiac magnetic resonance (CMR) it is a technique without radiation, which is considered the gold-standard for the evaluation of cardiac anatomy, function and even tissue composition. The RESILIENCE trial will use CMR as the main outcome measure methodology, and patients enrolled in the trial will undergo 3 scans across the duration of the study.
Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic Conditioning (RIC) in Non-Hodgkin lymphoma (NHL) patients receiving anthracyclines. Patients scheduled to undergo ≥5 chemotherapy cycles will be eligible.
Cancer survivors are at high risk for cardiovascular complications. Anthracyclines are an extremely effective treatment against many cancer types, but they can induce cardiac toxicity resulting in chronic heart failure.
RESILIENCE tests a novel preventive intervention (remote ischemic conditioning) in patients at risk for anthracycline-induced cardiotoxicity. In addition, new diagnostic modalities will be used to identify anthracyclines-induced cardiotoxicity in its very early stages.
RESILIENCE counts on a multidisciplinary consortium with the active participation of patients.
A new center joins the RESILIENCE project. It is the hospital La Paz in Madrid,…
The new Clinical Practice Guidelines of Cardio-Oncology were released in August 2022. RESILIENCE is proud…
We have had the opportunity to talk about resilience with two great figures of Spanish…
On Thursday, November 17th we participated in the XXII Week of Science and Innovation in…
What does #Resilience mean to you? 🤔 For @juliogarciamera, Spanish sports star, it is the ability to overcome adversity. 💬 He spoke about it with the director of #RESILIENCEh20202, Dr. @Borjaibanez1 in this interview 🎬 https://t.co/O7F3OTBW7E Read More
🔸 It is considered the most accurate for assessing the shape, function and composition of heart tissues. 🔸 Members of the #RESILIENCEh2020 team have succeeded in developing a revolutionary technique to reduce CMR image acquisition time. Read More
#AboutRESILIENCE 🔍 Cardiac magnetic resonance imaging (CMR) is the primary tool for assessing the results of our clinical trial, but why? 🧐 🔸 It is an imaging test in which patients do not receive radiation. https://t.co/yQLn6rDRgN Read More
RT @CNIC_CARDIO: El 🗓️ 6 de febrero acaba el plazo para el puesto de Técnico de Imagen para ensayo clínico @resilienceH2020 Requisitos: T… Read More
Thanks to the great scientific and medical advances, the prevalence of cancer survivors in increasing in Europe. However, cancer survivors are at high risk for cardiovascular complications. Among them, heart failure is especially worrisome. There is a strong need to reduce the burden of disability in cancer survivors and to increase their quality of life.
Remote Ischemic Conditioning (RIC) is a phenomenon by which brief, reversible episodes of occlusion and re-occlusion in one organ (e.g. an arm) render remote organs resistant to injury.
Cardiac magnetic resonance (CMR) it is a technique without radiation, which is considered the gold-standard for the evaluation of cardiac anatomy, function and even tissue composition.
Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic Conditioning (RIC) in Non-Hodgkin lymphoma (NHL) patients receiving anthracyclines. Patients scheduled to undergo ≥5 chemotherapy cycles will be eligible.
Non-Hodgkin Lymphoma (NHL) treatment includes the use of anthracyclines within a homogeneous combination chemotherapy. NHL are specially vulnerable to anthracycline-induced heart failure. NHL affects similarly women and men, and it it thus ideal to study gender differences in cardiotoxicity.
Read the most recent scientific advances in the field by RESILIENCE partners.
Read the most recent newsletters, press releases, and other information about RESILIENCE in layperson´s language.
Are you a patient participating in RESILIENCE? Here you will find useful information about the details of your participation, activities specifically designed for you. You will also be able to contact RESILIENCE researchers.
Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischemic Conditioning.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |